- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07696364
Evaluation of the Anti-septic Effect of a Chlorhexidine (CHX) Mouthwash With or Without an Anti-Discoloration System (ADS) During Experimental Gingivitis
Protocol Title Evaluation of the Anti-septic Effect of a Chlorhexidine (CHX) Mouthwash With or Without an Anti-Discoloration System (ADS) Compared to Placebo, During Experimental Gingivitis
Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.
Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation.
During the study period, participants will be asked to rinse with the mouthrinse sample or the placebo for 60 seconds twice daily, under video supervision (participants send in video recordings of their rinsing to control adherence to the protocol). A dental assistant, unaware of the study's purpose, will distribute the samples. The containers will be unlabeled, ensuring that both the participants and examiners are blinded to group allocation.
At Days 0, 7, 14 and 21 of the experiment, clinical examinations will be performed from central incisors to the second molars in each participant. The Discoloration Index (DI17) will be recorded at three aspects on each tooth (mesial, buccal and distal). The criteria for the Discoloration Index (DI) are indicated in Table 1. Plaque and Gingivitis Indices will be assessed at 4 aspects of each tooth (mesial, buccal, distal and lingual) using the criteria of the Plaque Index system (PlI) (Silness & Löe 1964) and the Gingival Index System (GI) (Löe & Silness 1963) 16, 18. At each visit, the parameters will be assessed by the same examiner, who will be masked by the allocation of the test and control to avoid examiner bias and calibration bias.
Upon completion of the experimental period, mechanical daily plaque control measures will be re-instated and the participants will be re-examined after 3 weeks to ensure their periodontal health. Following the experimental period, another professional cleansing will be performed to remove plaque and possible stain on the teeth. At day 35 the participants will be checked again.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Canton of Bern
-
Bern, Canton of Bern, Schweiz, 3010
- Department of Periodontology, University of Bern
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- systemically healthy,
- non-smoker, former smokers > 5 years,
- at least 24 teeth,
- clinical diagnosis of periodontal health or gingivitis as determined by pocket probing depth not exceeding 4 mm with concomitant bleeding on probing.
Exclusion Criteria:
- clinically visible carious lesions,
- systemic antibiotics within 3 months prior to enrolment
- vulnerable persons
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo Group
Group P rinses twice daily with 10 ml of a placebo (pure water with flavored additive) solution
|
After a preparatory phase of prophylaxis and 3 weeks of optimal oral hygiene practice, the plaque and gingivitis scores of the participants will approach zero.
The participants will then be asked to abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.
|
|
Eksperimentel: Group T1
Group T1 rinses twice daily with 10 ml of 0.12% chlorhexidine solution with ADS (Anti-Discoloration System) solution (Curasept ADS 212)
|
After a preparatory phase of prophylaxis and 3 weeks of optimal oral hygiene practice, the plaque and gingivitis scores of the participants will approach zero.
The participants will then be asked to abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.
|
|
Eksperimentel: Group T2
Group T2 rinses twice daily with 10 ml of 0.12% chlorhexidine with HA (Hyaluronic Acid)
|
After a preparatory phase of prophylaxis and 3 weeks of optimal oral hygiene practice, the plaque and gingivitis scores of the participants will approach zero.
The participants will then be asked to abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
Tidsramme: at day 21
|
The index is a scoring system 0, 1, 2, or 3 where 0 is defining normal gingiva to 3 representing severe inflammation with spontaneous bleeding
|
at day 21
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
Tidsramme: at day 0, 7, 14, and 35
|
The index is a scoring system 0, 1, 2, or 3 where 0 is defining normal gingiva to 3 representing severe inflammation with spontaneous bleeding
|
at day 0, 7, 14, and 35
|
|
Plaque accumulation, assessed by the Plaque Index Silness and Löe 1994
Tidsramme: at day 0, 7, 14, 21 and 35
|
The index is a scoring system assessing the plaque at 4 surfaces of the teeth, starting at 0 for no plaque visible to 3 with an abundance of plaque creating a thick layer that fills the interdental space.
|
at day 0, 7, 14, 21 and 35
|
|
Staining assessed by the Discoloration index
Tidsramme: at day 0, 7, 14, 21 and 35
|
The discoloration is an index from 0: no discoloration to 3: Heavy brown and black discoloration over the entire extent of the tooth surface, black discoloration predominantly on the interproximal surfaces
|
at day 0, 7, 14, 21 and 35
|
|
Oral scan
Tidsramme: at day 0, 21 and 35
|
Oral scans will be performed to study changes in gingival texture, volume and colour or other changes
|
at day 0, 21 and 35
|
|
Microbiological changes
Tidsramme: at day 0, 21 and 35
|
Changes in 8 periodontopathogens will be assessed by Multiplex PCR
|
at day 0, 21 and 35
|
|
Characterisation of host- and microbiome-derived metabolites
Tidsramme: at day 0, 21 and 35
|
From selective participants, host-derived metabolites will be assessed by untargeted liquid chromatography-mass spectrometry (LC-MS) to study molecular changes throughout disease progression and possible relationships with other generated datasets.
|
at day 0, 21 and 35
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- V4ExpAugGingivitis
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Gingivitis Infection
-
Jianfeng XieRekrutteringCLABSI - Central Line Associated Bloodstream InfectionKina
-
Fondazione Policlinico Universitario Agostino Gemelli...Lo.Li.Pharma s.r.lIkke rekrutterer endnuHPV - Anogenital Human Papilloma Virus Infection | Infertilitet
-
Mahidol UniversityAfsluttetCLABSI - Central Line Associated Bloodstream InfectionThailand
-
University of BelgradeAktiv, ikke rekrutterendeParadentose | Gingivitis og periodontale sygdommeSerbien
-
University of Santiago de CompostelaOsteology FoundationRekruttering
-
State University of New York at BuffaloRekruttering
-
Abant Izzet Baysal UniversityRekrutteringParadentose | Gingivitis og periodontale sygdommeTyrkiet (Türkiye)
-
Ankara UniversityThe Scientific and Technological Research Council of TurkeyAfsluttetPlaque-induceret gingivitisTyrkiet (Türkiye)
-
University of GaziantepIkke rekrutterer endnuHPV - Anogenital Human Papilloma Virus Infection | Kræft, sund | Sundheds tro model
-
Assiut UniversityIkke rekrutterer endnuCLABSI - Central Line Associated Bloodstream Infection | Perifert indsat central kateter | Umbilical venekateter
Kliniske forsøg med Experimental gingivitis model
-
University of ParmaAfsluttetMotorisk aktivitet | Hemiplegisk cerebral pareseItalien
-
Biruni UniversityAfsluttetSund og rask | Paradentose | GingivitisKalkun
-
Otolith LabsMCRAAfsluttetBPPV | Svimmelhed | Godartet Paroxysmal Positionel Vertigo | Vestibulær migræne | Vestibulær lidelse | Menieres sygdom | Ménières Vertigo | Labrynthitis | Migræne Associated Vertigo | Ukompenseret ensidig vestibulopatiForenede Stater
-
Çankırı Karatekin UniversityAfsluttetHjertefejl | Nyresvigt | Gastro esophageal refluks | Copd | Intensiv afdelings syndromKalkun
-
Hacettepe UniversityAfsluttetEffekten af Humeral Head Depressor Muscle Co-Activation Training i form af funktionelle resultaterKirurgi | Rotator Cuff RiverKalkun
-
University of TorontoCanadian Institutes of Health Research (CIHR)RekrutteringStillesiddende adfærd | Metabolisk forstyrrelseCanada
-
University of WashingtonColgate PalmoliveAfsluttetPlaque-induceret tandkødsbetændelseForenede Stater
-
University of ChileUkendt